MedImmune AstraZeneo



ESMO 2018 Industry Satellite Symposium

EGFR-mutated NSCLC:

A data-driven approach to optimising patient outcomes

ICM – Room 14b, Messe Munich Munich, Germany Sunday 21 October 2018, 13.00–14.30

Chair: Jürgen Wolf (Germany)

Agenda

First-line treatment of patients with EGFR-mutated advanced NSCLC Suresh Ramalingam (USA)

The importance of biomarker testing in identifying optimal treatments in advanced NSCLC **David Gonzalez de Castro (UK)**

Treatment options after disease progression on an EGFR-TKI Myung-Ju Ahn (South Korea)

Panel discussion: Optimal treatment sequencing in EGFR-mutated advanced NSCLC **Faculty**

Audience Q&A Faculty and audience

Light refreshments are available prior to the symposium

This scientific satellite symposium is funded and organised by AstraZeneca Global

VPM ID: DE-15613 | Date of preparation: July 2018 | Expiry date: November 2018 AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK